Emergent Suspends COVID-19 Vaccine API Manufacturing As US FDA Inspects Bayview Plant
Executive Summary
After discovery of viral vector cross-contamination, AstraZeneca quit, J&J took control and the FDA launched inspection.
You may also be interested in...
Coronavirus Update: J&J Highlights Positive Booster Shot Data
Also, Moderna completed the submission of the BLA for mRNA-1273’s FDA approval, Pfizer starts a rolling submission for a booster shot and Brii Biosciences announced data for its two-antibody antiviral cocktail, and Japan withdraws selected lots of Moderna's vaccine over contamination worries.
Memo To File: How US FDA Decided Which Janssen Vaccine Drug Substance Batches Were OK To Use
Two batches were authorized because they were made before production waste jammed Emergent BioSolutions' Bayview plant.
What To Do When Last Pandemic’s Answer To The Next Pandemic Falters: Point Fingers
US congressional ‘coronavirus crisis’ panel explores Emergent BioSolutions COVID-19 vaccine launch failures while scoring points about private sector support.